Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ubiquitin-Proteasome System Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UBA52 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBA52 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View UBA52 Products |
| Gene Delivery | UBA52 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View UBA52 Products |
| Benchmark Ab | Anti-UBA52 Recombinant positive control. |
View UBA52 Products |
| Validator | UBA52 siRNA Set For knockdown verification. |
View UBA52 Products |
| Related Target A | MDM2 Key E3 ubiquitin ligase regulating p53 degradation. |
View MDM2 Products |
| Related Target B | RPS27A Another major ubiquitin-ribosomal protein fusion gene. |
View RPS27A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing free Ubiquitin vs Fusion | High-purity recombinant proteins (>95%) strictly verified by mass spec for molecular weight. |
| Translational Regulation Assays | Full-length ORF lentivirus preserving native cellular expression and processing. |
| Lack of Controls | Clinical Benchmark Antibodies included for rigorous assay calibration. |
| False Positives in Knockdown | Validated siRNA included for specificity checks and background reduction. |
Live UBA52 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting the Ubiquitin-Proteasome System (UPS) is intensifying, with major players shifting focus from traditional inhibitors to targeted protein degradation (PROTACs/Molecular Glues). As foundational components like UBA52 are critical for both cellular ubiquitin pools and ribosomal biogenesis (via RPL40), the next wave of R&D is targeting the precise modulation of these pathways in oncology and neurodegeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Glues | Arvinas, Nurix | Solid Tumors, Heme Malignancies | Ubiquitination Assays (Need high-purity components) |
| Small Molecules | Takeda, Novartis | Neurodegeneration | Selectivity Assay (Need Mutant vs WT Proteins) |
| RNAi / ASO | Alnylam, Ionis | Rare Genetic Disorders | Knockdown Validation (Need Sequence-verified siRNA) |